Acalabrutinib vs Ibrutinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Mantle Cell Lymphoma

Shared mechanism: BTK · full Mantle Cell Lymphoma pipeline

Acalabrutinib

Marketed by AstraZeneca

Approved in Mantle Cell Lymphomasmall molecule (BTK inhibitor)
Weak signal

NCT02213926 · Phase 2 · active, not recruiting

This was a single-arm, open-label study without randomization, blinding, or a comparator. Although the clinical response endpoint was reported in 124 participants, a comparative treatment effect could not be tested, so the evidence is limited.

Next expected readout: December 2026 · NCT04115631 (registry estimate)

Reported efficacy

Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants (not_applicable)

Result source: NCT02213926

Ibrutinib

Marketed by AbbVie and partners

Phase 3 in Mantle Cell Lymphomasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT01479842 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Mantle Cell Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Ibrutinib: registry results are on file for Mantle Cell Lymphoma, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Acalabrutinib
Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants NCT02213926 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Chronic Lymphocytic Leukemia

Shared mechanism: BTK · full Chronic Lymphocytic Leukemia pipeline

Acalabrutinib

Marketed by AstraZeneca

Approved in Chronic Lymphocytic Leukemiasmall molecule (BTK inhibitor)
Partial signal

NCT02475681 · Phase 3 · completed

This was a randomized phase 3 trial of 535 people with an active comparator and a hard progression-free survival endpoint that was clearly met. Only outcome assessors were masked and treatment was open-label, so it is graded below the highest tier.

Next expected readout: December 2026 · NCT05971251 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Acalabrutinib 38.4 Months (95% CI 33 to 38.6) | Ibrutinib 38.4 Months (95% CI 33 to 41.6) (met)

Result source: NCT02477696

Ibrutinib

Marketed by AbbVie and partners

Approved in Chronic Lymphocytic Leukemiasmall molecule
Partial signal

NCT01578707 · Phase 3 · completed

This was a large randomized, active-controlled trial of ibrutinib versus ofatumumab, with progression-free survival as a clinical primary endpoint and a statistically significant favorable result for ibrutinib. However, treatment was open-label rather than double-blinded, so the evidence is graded moderate despite the strong primary result.

Next expected readout: December 2026 · NCT03513562 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Up to 5 years): Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) (met)

Result source: NCT01611090

Results for Chronic Lymphocytic Leukemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Acalabrutinib: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Ibrutinib
Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) NCT01611090 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acalabrutinib's landscape · Ibrutinib's landscape